Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578441 | 0.82 | PTGES (0.47) | DGAT1GCKKCNH2SOAT1EPHX2 | |
| SCHEMBL4096749 | 0.75 | PTGES (0.47) | TEAD1PPARASCN9A | |
| SCHEMBL3573981 | 0.73 | PPARG (0.41) | DGAT1KCNH2SOAT1LIPGLPL | |
| SCHEMBL3577884 | 0.72 | GCK (0.41) | DGAT1GCKKCNH2SOAT1ACACB | |
| SCHEMBL4101074 | 0.72 | PTGES (0.54) | TEAD1PPARASCN9A | |
| SCHEMBL3576199 | 0.71 | PPARG (0.40) | DGAT1KCNH2LIPGLPLPPARD | |
| SCHEMBL4089205 | 0.70 | PTGES (0.56) | TEAD1PPARASCN9A | |
| SCHEMBL4097221 | 0.70 | PTGES (0.55) | TEAD1PPARDSCN9A | |
| SCHEMBL3017912 | 0.69 | PPARA (0.37) | DGAT1KCNH2PPARDPPARAADORA2A | |
| SCHEMBL3582187 | 0.67 | PTGES (0.67) | TEAD1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | DGAT1 4718/4885GCK 2322/4885KCNH2 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.